MedTrace Logo

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

NCT04182581 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-12-02

No results posted yet for this study

Summary

The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T therapy.

Conditions

Interventions

BIOLOGICAL

BCMA/CD19 Dual-Target CAR-T

BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.

Sponsors & Collaborators

  • Gracell Biotechnology Ltd.

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Xiequn Chen, Doctor · First affiliated hospital of air force military medical university(i.e., Xijing Hopital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2020-09-30
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04182581 on ClinicalTrials.gov